Interim findings show promise in decreasing shortness of breath from hypertrophic cardiomyopathy

Credit: Unsplash / CC0 Public Domain

A new drug has promised to help people with heart disease who suffer from shortness of breath, according to the conclusion of a study presented today at the American Academy of Sciences (ACC) in Washington, DC

Florian Rader, MD, MSc, professor of cardiology and medical director of the Center for Hypertension at the Smidt Heart Center in Cedars-Sinai, presented the results of an international trial showing that the drug, mavacamten, facilitated . respiratory failure in patients with obstructive pulmonary disease hypertrophic cardiomyopathy.

The nature of the organism results in the thickness of the heart muscle, and as a result. heart muscle Cells grow and the stain often develops between cells. Patients with this condition usually experience shortness of breath, chest compressions, frequent heartbeats, and, although not uncommon, sudden cardiac arrest.

“Still, the treatment of hypertrophic cardiomyopathy has been ineffective, leaving many patients with symptoms and often, in need of abuse or even. open-heart surgery“Says Rader, who served as chief clinical research researcher at Cedars-Sinai and a leading ACC authoritative writer for the heart in hypertrophic cardiomyopathy. in the symptoms and an important measure of heart disease.

As Rader, executive director of the Center for the Treatment of Hypertrophic Cardiomyopathy at Cedars-Sinai, explains in a late-stage presentation, mavacamten demonstrates initial success in eliminating symptoms associated with the condition – especially shortness of breath, which will may be weak for patients with heart disease. .

Key data from clinical trials — shared by Rader on ACC22 — include:

  • The mean age of the 231 clinical trials participants was 60 years, and 39% of those on the test were female. The average follow-up was 62 weeks.
  • 69% of test participants improved shortness of breath after 48 weeks of treatment.
  • Treatment with mavacamten is generally well tolerated, and no new safety concerns are found during long-term follow-up.

Since the condition was first described 60 years ago, Rader said no specific treatment options have been developed.

While the incidence of hypertrophic cardiomyopathy is about 1 in every 200 patients, Rader said the underlying condition is not well understood.

“Most patients have the condition – and often feel short of breath or heartbeat – but their doctor does not recognize these symptoms as they arise from hypertrophic cardiomyopathy,” Rader said. “Instead, their doctors may tell patients that they have no plan, need to lose weight or are suffering from anxiety.”

The best way, according to Rader, is to start treating the patient’s symptoms first. If shortness of breath is a major concern, the doctor should listen to the patient’s heart for complaints, followed by an electrocardiogram, and, finally, an echocardiogram, which will usually result in an accurate diagnosis.

Christine M. Albert, MD, MPH, professor, head of the Department of Cardiology and Lee and Harold Kapelovitz Distinguished Chair in Cardiology, said this. treatment options It is designed specifically for hypertrophic cardiomyopathy — a welcome change for patients who have suffered for years.

“This is the highest and longest report of mavacamten in hypertrophic patients cardiomyopathy, “said Albert, who also joins the ACC.” We are encouraged to learn that it reaffirms health and effectiveness. We are proud to be at the forefront of bringing this treatment to patients. “

The drug was developed by Bristol Myers Squibb and approved by the US Food and Drug Administration.

Experiments show the effectiveness of the drug in almost 80% of patients with hypertrophic cardiomyopathy

hintPreliminary research shows promise to reduce respiratory failure from hypertrophic cardiomyopathy (2022, April 3) restored 3 April 2022 from .html

This document is copyrighted. Apart from any genuine transaction for the purpose of personal analysis or investigation, no part may be reproduced without our written permission. Content is provided for informational purposes only.

Interim findings show promise in decreasing shortness of breath from hypertrophic cardiomyopathy Source link Interim findings show promise in decreasing shortness of breath from hypertrophic cardiomyopathy

Related Articles

Back to top button